SecurityTGXSF / Tigenix Sa
InstitutionCormorant Asset Management, LLC
Shares9,972,386
Ownership 3.37%

Cormorant Asset Management, LLC discloses 3.37% ownership in TGXSF / Tigenix Sa

February 14, 2018 - Cormorant Asset Management, LLC has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 9,972,386 shares of Tigenix Sa (OTC:TGXSF). This represents 3.37 percent ownership of the company. In their previous filing dated February 14, 2017, Cormorant Asset Management, LLC had reported owning 14,472,631 shares, indicating a decrease of -31.09 percent.

13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Reported
Shares
Change in Shares
(Percent)
Ownership
(Percent)
Change in Ownership
(Percent)
2018-02-14 2018-02-14 SC 13G/A 14,472,631 9,972,386 -31.09 3.37 -42.20
2017-02-14 2017-02-14 SC 13G 12,150,794 14,472,631 19.11 5.83 19.22
2016-12-23 2016-12-23 SC 13G 14,601,663 5.88

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Cormorant Asset Management, LLC discloses 3.37%  ownership in TGXSF / Tigenix Sa

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-06-30 13F-HR TIGENIX SPONSORED ADS 88675R109 0 -100.00 0 -100.00 0 0
2017-03-31 13F-HR TIGENIX SPONSORED ADS 88675R109 15.09 129,032 0.00 2,013 7.02 0 132 7.02
2016-12-31 13F-HR TIGENIX SPONSORED ADS 88675R109 129,032 1,881

Related SEC Filings

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

Tigenix SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-07-13 sec.gov
Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     TiGenix   (Name of Issuer)         ordinary shares, no nominal value per share         (Title of Class of Securities)                 88675R 10 9                 (CUSIP Number)                 December 20, 2016                 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate t

Related News Stories

Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix | Business Wire

2018-05-23 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, in two separate, but concurrent and related offers in Belgium (the “Belgian Offer”) and in the United States (the “U.

Shire bid marks Takeda’s latest and biggest push for global status

2018-04-26 japantimes.co.jp
Takeda Pharmaceutical Co. Ltd..’s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan’s most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. (3-0)

Shire bid marks Takeda's latest - and biggest - push for global status

2018-04-25 reuters
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd’s (4502.T) $64 billion bid for London-listed rare disease specialist Shire Plc (SHP.L) bolsters its credentials as Japan’s most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making. (3-0)

Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018 | Business Wire

2018-04-25 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the first acceptance period of its previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, at an acquisition price of EUR 1.

UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

2018-04-25 biospace
Takeda Pharmaceutical has come back with an improved bid for Shire for $64 billion, making it the fifth round of talks. Shire is willing to recommend to the board to accept the offer with an extended deal deadline of May 8. (5-0)



CUSIP: 88675R109